Inventiva：在 Lanifibranor 上市前，MASH 市场正演变为联合用药市场 ($IVA)
· seekingalpha.com
Inventiva 定位为一项高风险的临床催化剂投资，其口服全 PPAR 激动剂 lanifibranor 正针对代谢功能障碍相关脂肪性肝炎 (MASH) 进行研发。在此阅读更多关于 $IVA 股票的信息。
My current perspective on Inventiva ( IVA ) comes from a counterintuitive view of the competitive landscape. Although approvals were granted for both Rezdiffra ...